Advances and hurdles on the way toward a leprosy vaccine

Human Vaccines

Volumn 7, Issue 11, 2011, Pages 1172-1183

  Duthie, Malcolm S ^a   Gillis, Thomas P ^b   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Leprosy; Mycobacteria; T cell; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; BCG VACCINE; CLOFAZIMINE; DAPSONE; LEPROSY VACCINE; OFLOXACIN; PLACEBO; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; BACTERIAL TRANSMISSION; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; HEALTH CARE NEED; HUMAN; INFECTION PREVENTION; INFECTION RATE; LEPROSY; LEPROSY CONTROL; MONOTHERAPY; MULTIBACILLARY LEPROSY; NONHUMAN; RECURRENT INFECTION; REVIEW; STRATEGIC PLANNING; TREATMENT DURATION; TUBERCULOSIS;

EID: 81855224516     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.11.16848     Document Type: Review

References (144)

1. WHO. Global leprosy situation. Wkly Epidemiol Rec 2010; 85:337-48; PMID:20830851.
2. Bakker MI, Hatta M, Kwenang A, Van Mosseveld P, Faber WR, Klatser PR, et al. Risk factors for developing leprosy - a population-based cohort study in Indonesia. Lepr Rev 2006; 77:48-61; PMID:16715690.
3. Moet FJ, Pahan D, Schuring RP, Oskam L, Richardus JH. Physical distance, genetic relationship, age and leprosy classification are independent risk factors for leprosy in contacts of patients with leprosy. J Infect Dis 2006; 193:346-53; PMID:16388481; DOI:10.1086/499278.
4. Goulart IM, Bernardes Souza DO, Marques CR, Pimenta VL, Goncalves MA, Goulart LR. Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts. Clin Vaccine Immunol 2008; 15:101-5; PMID:17989339; DOI:10.1128/CVI.00372-07.
5. Bakker MI, Hatta M, Kwenang A, Klatser PR, Oskam L. Epidemiology of leprosy on five isolated islands in the Flores Sea, Indonesia. Trop Med Int Health 2002; 7:780-7; PMID:12225510; DOI:10.1046/j.1365-3156.2002.00931.x.
6. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 1966; 34:255-73; PMID:5950347.
7. Scollard DM. Classification of leprosy: a full color spectrum or black and white? Int J Lepr Other Mycobact Dis 2004; 72:166-8; PMID:15301586; DOI: 10.1489/1544-581X(2004)072〈0166:COLAFC〉2.0.CO;2.
8. Joyce MP, Scollard DM. Leprosy (Hansen's Disease). In: Conn's Current Therapy. Edited by Bope ET: Saunders 2004; 100-5.
9. WHO. Global leprosy situation. Wkly Epidemiol Rec 2009; 84:333-40; PMID:19685606.
10. Duthie MS, Hay MN, Rada EM, Convit J, Ito L, Oyafuso LK, et al. Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers. Eur J Clin Microbiol Infect Dis 2011.
11. Gelber RH, Balagon VF, Cellona RV. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int J Lepr Other Mycobact Dis 2004; 72:493-500; PMID:15755209; DOI:10.1489/1544-581X(2004)72〈493: TRRIML〉2.0.CO;2.
12. Honrado ER, Tallo V, Balis AC, Chan GP, Cho SN. Noncompliance with the world health organization-multidrug therapy among leprosy patients in Cebu, Philippines: its causes and implications on the leprosy control program. Dermatol Clin 2008; 26:221-9; PMID:18346553; DOI:10.1016/j.det.2007.11.007.
13. Roche PW, Neupane KD, Failbus SS, Butlin CR. Dapsone drug resistance in the MDT era. Int J Lepr Other Mycobact Dis 2000; 68:323-5; PMID:11221097.
14. Ellard GA, Pannikar VK, Jesudasan K, Christian M. Clofazimine and dapsone compliance in leprosy. Lepr Rev 1988; 59:205-13; PMID:3200085.
15. Chen XS, Li WZ, Jiang C, Ye GY. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy. Int J Lepr Other Mycobact Dis 1999; 67:379-87; PMID:10700911.
16. Chen XS, Li WZ, Jiang C, Ye GY. Studies on risk of leprosy relapses in China: relapses after treatment with dapsone monotherapy. Int J Lepr Other Mycobact Dis 1999; 67:371-8; PMID:10700910.
17. Cellona RV, Balagon MF, dela Cruz EC, Burgos JA, Abalos RM, Walsh GP, et al. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. Int J Lepr Other Mycobact Dis 2003; 71:308-19; PMID:14763888; DOI:10.1489/1544-581X(2003)071〈0308: LEOYWM〉2.0.CO;2.
18. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev 2000; 71:144-53; PMID:10920610.
19. Norman G, Joseph G, Richard J. Relapses in multibacillary patients treated with multi-drug therapy until smear negativity: findings after twenty years. Int J Lepr Other Mycobact Dis 2004; 72:1-7; PMID:15217321; DOI:10.1489/1544-581X(2004)072〈0001:RIMPTW〉2.0.CO;2.
20. Ji B, Jamet P, Sow S, Perani EG, Traore I, Grosset JH. High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Antimicrob Agents Chemother 1997; 41:1953-6; PMID:9303392.
21. Cambau E, Bonnafous P, Perani E, Sougakoff W, Ji B, Jarlier V. Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin Infect Dis 2002; 34:39-45; PMID:11731943; DOI:10.1086/324623.
22. Maeda S, Matsuoka M, Nakata N, Kai M, Maeda Y, Hashimoto K, et al. Multidrug resistant Mycobacterium leprae from patients with leprosy. Antimicrob Agents Chemother 2001; 45:3635-9; PMID:11709358; DOI:10.1128/AAC.45.12.3635-9. 2001.
23. Matsuoka M, Kashiwabara Y, Liangfen Z, Goto M, Kitajima S. A second case of multidrug-resistant Mycobacterium leprae isolated from a Japanese patient with relapsed lepromatous leprosy. Int J Lepr Other Mycobact Dis 2003; 71:240-3; PMID:14608820; DOI:10.1489/1544-581X(2003)71〈240:ASCOMM〉2.0.CO;2.
24. Matsuoka M, Kashiwabara Y, Namisato M. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin. Int J Lepr Other Mycobact Dis 2000; 68:452-5; PMID:11332288.
25. Grosset JH, Guelpa-Lauras CC, Bobin P, Brucker G, Cartel JL, Constant-Desportes M, et al. Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Int J Lepr Other Mycobact Dis 1989; 57:607-14; PMID:2674301.
26. Williams DL, Gillis TP. Molecular detection of drug resistance in Mycobacterium leprae. Lepr Rev 2004; 75:118-30; PMID:15282962.
27. Matsuoka M, Budiawan T, Aye KS, Kyaw K, Tan EV, Cruz ED, et al. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines. Lepr Rev 2007; 78:343-52; PMID:18309708.
28. Manjunatha UH, Lahiri R, Randhawa B, Dowd CS, Krahenbuhl JL, Barry CE. Mycobacterium leprae is naturally resistant to PA-824. Antimicrob Agents Chemother 2006; 50:3350-4; PMID:17005816; DOI:10.1128/AAC.00488-06.
29. You EY, Kang TJ, Kim SK, Lee SB, Chae GT. Mutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea. J Infect 2005; 50:6-11; PMID:15603834; DOI:10.1016/j.jinf.2004.03.012.
30. WHO. Meeting on Sentinel Surveillance for Drug Resistance in Leprosy. In: WHO Technical Report Series. Geneva: World Health Organization 2011.
31. Gelber RH. Chemotherapy of lepromatous leprosy: recent developments and prospects for the future. Eur J Clin Microbiol Infect Dis 1994; 13:942-52; PMID:7698121; DOI:10.1007/BF02111496.
32. Gelber RH, Murray LP, Siu P, Tsang M, Rea TH. Efficacy of minocycline in single dose and at 100 mg twice daily for lepromatous leprosy. Int J Lepr Other Mycobact Dis 1994; 62:568-73; PMID:7868955.
33. Gelber RH, Siu P, Tsang M, Richard V, Chehl SK, Murray LP. Activity of combinations of dapsone, rifampin, minocycline, clarithromycin and sparfloxacin against M. leprae-infected mice. Int J Lepr Other Mycobact Dis 1995; 63:259-64; PMID:7602221.
34. Ji B, Grosset J. Ofloxacin for the treatment of leprosy. Acta Leprol 1991; 7:321-6; PMID:1950440.
35. Ji B, Grosset J. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev 2000; 71:81-7; PMID:11201894.
36. Ji B, Perani EG, Petinom C, N'Deli L, Grosset JH. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob Agents Chemother 1994; 38:662-7; PMID:8031029.
37. De Rojas V, Hernandez O, Gil R. Some factors influencing delay in leprosy diagnosis. Bull Pan Am Health Organ 1994; 28:156-62; PMID:8069335.
38. Chen XS, Li WZ, Jiang C, Ye GY. Leprosy in China: delay in the detection of cases. Ann Trop Med Parasitol 2000; 94:181-8; PMID:10827873; DOI:10.1080/00034980057527.
39. Deps PD, Guedes BV, Bucker Filho J, Andreatta MK, Marcari RS, Rodrigues LC. Delay in the diagnosis of leprosy in the Metropolitan Region of Vitoria, Brazil. Lepr Rev 2006; 77:41-7; PMID:16715689.
40. Lockwood DN, Reid AJ. The diagnosis of leprosy is delayed in the United Kingdom. QJM 2001; 94:207-12; PMID:11294963; DOI:10.1093/qjmed/94.4.207.
41. Siddiqui MR, Velidi NR, Pati S, Rath N, Kanungo AK, Bhanjadeo AK, et al. Integration of leprosy elimination into primary health care in orissa, India. PLoS ONE 2009; 4:8351; PMID:20020051; DOI:10.1371/journal. pone.0008351.
42. Ferreira J, Mengue SS, Wagner MB, Duncan BB. Estimating hidden prevalence in Hansen's disease through diagnosis delay and grade of disability at time of diagnosis. Int J Lepr Other Mycobact Dis 2000; 68:464-73; PMID:11332290.
43. Nicholls PG, Croft RP, Richardus JH, Withington SG, Smith WC. Delay in presentation, an indicator for nerve function status at registration and for treatment outcome-the experience of the Bangladesh Acute Nerve Damage Study cohort. Lepr Rev 2003; 74:349-56; PMID:14750580.
44. Van Veen NH, Meima A, Richardus JH. The relationship between detection delay and impairment in leprosy control: a comparison of patient cohorts from Bangladesh and Ethiopia. Lepr Rev 2006; 77:356-65; PMID:17343222.
45. Lockwood DN, Suneetha S. Leprosy: too complex a disease for a simple elimination paradigm. Bull World Health Organ 2005; 83:230-5; PMID:15798849.
46. WHO. Global leprosy situation. Wkly Epidemiol Rec 2005; 80:289-95; PMID:16149384.
47. WHO. Global leprosy situation. Wkly Epidemiol Rec 2007; 82:225-32; PMID:17585406.
48. Meima A, Richardus JH, Habbema JD. Trends in leprosy case detection worldwide since 1985. Lepr Rev 2004; 75:19-33; PMID:15072123.
49. Meima A, Smith WC, van Oortmarssen GJ, Richardus JH, Habbema JD. The future incidence of leprosy: a scenario analysis. Bull World Health Organ 2004; 82:373-80; PMID:15298228.
50. Setia MS, Steinmaus C, Ho CS, Rutherford GW. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis 2006; 6:162-70; PMID:16500597; DOI:10.1016/S1473-3099(06)70412-1.
51. Merle CS, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 2010; 9:209-22; PMID:20109030; DOI:10.1586/erv.09.161.
52. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284:1520-3; PMID:10348738; DOI:10.1126/science.284.5419.1520.
53. Zodpey SP, Bansod BS, Shrikhande SN, Maldhure BR, Kulkarni SW. Protective effect of Bacillus Calmette Guerin (BCG) against leprosy: a population-based case-control study in Nagpur, India. Lepr Rev 1999; 70:287-94; PMID:10603718.
54. Zodpey SP, Ambadekar NN, Thakur A. Effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case-control study in Yavatmal District, India. Public Health 2005; 119:209-16; PMID:15661132; DOI:10.1016/j.puhe.2004.04.007.
55. Rodrigues LC, Kerr-Pontes LR, Frietas MV, Barreto ML. Long lasting BCG protection against leprosy. Vaccine 2007; 25:6842-4; PMID:17728023; DOI:10.1016/j.vaccine.2007.07.032.
56. Shepard CC, van Landingham R, Walker LL. Searches among mycobacterial cultures for antileprosy vaccines. Infect Immun 1980; 29:1034-9; PMID:7000701.
57. Shepard CC, van Landingham RM, Walker LL, Ye SZ. Comparison of the immunogenicity of vaccines prepared from viable Mycobacterium bovis BCG, heat-killed Mycobacterium leprae, and a mixture of the two for normal and M. leprae-tolerant mice. Infect Immun 1983; 40:1096-103; PMID:6343239.
58. Convit J, Sampson C, Zuniga M, Smith PG, Plata J, Silva J, et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet 1992; 339:446-50; PMID:1346818; DOI:10.1016/0140-6736(92)91056-E.
59. KarongaPreventionTrialGroup. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996; 348:17-24; PMID:8691924; DOI:10.1016/S0140-6736(96)02166-6.
60. Pönnighaus JM, Fine PE, Sterne JA, Wilson RJ, Msosa E, Gruer PJ, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992; 339:636-9; PMID:1347338; DOI:10.1016/0140-6736(92)90794-4.
61. Gupte MD, Vallishayee RS, Anantharaman DS, Nagaraju B, Sreevatsa, Balasubramanyam S, et al. Comparative leprosy vaccine trial in south India. Indian J Lepr 1998; 70:369-88; PMID:10189587.
62. Sreevatsa, Desikan KV. Evaluation of the efficacy of candidate vaccines against M. leprae infection in mice. Indian J Lepr 1988; 60:252-9; PMID:3192974.
63. Bhide MB, Pradhan KS, Bapat CV. A vaccine from ICRC bacilli against M. leprae infection in mouse foot-pad. Lepr India 1978; 50:334-44; PMID:359922.
64. Sharma P, Mukherjee R, Talwar GP, Sarathchandra KG, Walia R, Parida SK, et al. Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years. Lepr Rev 2005; 76:127-43; PMID:16038246.
65. Truoc LV, Ly HM, Thuy NK, Trach DD, Stanford CA, Stanford JL. Vaccination against leprosy at Ben San Leprosy Centre, Ho Chi Minh City, Vietnam. Vaccine 2001; 19:3451-8; PMID:11348710; DOI:10.1016/S0264-410X(01)00052-4.
66. Singh NB, Lowe AC, Rees RJ, Colston MJ. Vaccination of mice against Mycobacterium leprae infection. Infect Immun 1989; 57:653-5; PMID:2643581.
67. Singh NB, Srivastava A, Gupta HP, Kumar A, Srivastava S. Induction of lepromin positivity in monkeys by a candidate antileprosy vaccine: Mycobacterium habana. Int J Lepr Other Mycobact Dis 1991; 59:317-20; PMID:2071989.
68. Wakhlu A, Gaur SP, Kaushal GP, Misra A, Asthana P, Sircar AR. Response of Mycobacterium habana vaccine in patients with lepromatous leprosy and their household contacts. A pilot clinical study. Lepr Rev 2001; 72:179-91; PMID:11495449.
69. Düppre NC, Camacho LA, da Cunha SS, Struchiner CJ, Sales AM, Nery JA, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg 2008; 102:631-8; PMID:18514242; DOI:10.1016/j.trstmh.2008.04.015.
70. Cunha SS, Alexander N, Barreto ML, Pereira ES, Dourado I, de Fatima Maroja M, et al. BCG Revaccination Does Not Protect Against Leprosy in the Brazilian Amazon: A Cluster Randomised Trial. PLoS Negl Trop Dis 2008; 2:167; PMID:18270542; DOI:10.1371/journal.pntd.0000167.
71. WHO. Global tuberculosis programme and global programme on vaccines. Statement on BCG revaccination for the prevention of tuberculosis. Wkly Epidemiol Rec 1995; 70:229-31; PMID:7669527.
72. Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY, de Brito SC, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005; 366:1290-5; PMID:16214599; DOI:10.1016/S0140-6736(05)67145-0.
73. Barreto ML, Pereira SM, Ferreira AA. BCG vaccine: efficacy and indications for vaccination and revaccination. J Pediatr (Rio J) 2006; 82:45-54; PMID:16826312; DOI:10.2223/JPED.1499.
74. Gelber RH, Brennan PJ, Hunter SW, Munn MW, Monson JM, Murray LP, et al. Effective vaccination of mice against leprosy bacilli with subunits of Mycobacterium leprae. Infect Immun 1990; 58:711-8; PMID:2407654.
75. Ngamying M, Sawanpanyalert P, Butraporn R, Nikasri J, Cho SN, Levy L, et al. Effect of vaccination with refined components of the organism on infection of mice with Mycobacterium leprae. Infect Immun 2003; 71:1596-8; PMID:12595485; DOI:10.1128/IAI.71.3.1596-8.2003.
76. Naito M, Matsuoka M, Ohara N, Nomaguchi H, Yamada T. The antigen 85 complex vaccine against experimental Mycobacterium leprae infection in mice. Vaccine 1999; 18:795-8; PMID:10580191; DOI:10.1016/S0264-410X(99)00327-8.
77. Ngamying M, Varachit P, Phaknilrat P, Levy L, Brennan PJ, Cho SN. Effects of vaccination with several mycobacterial proteins and lipoproteins on Mycobacterium leprae infection of the mouse. Int J Lepr Other Mycobact Dis 2001; 69:43-5; PMID:11480318.
78. Britton WJ, Martin E, Kamath AT, Neupane KD, Roche PW. Immunoprophylaxis against Mycobacterium leprae infection with subunit vaccines. Lepr Rev 2000; 71:176-81; PMID:11201878.
79. Roche PW, Neupane KD, Failbus SS, Kamath A, Britton WJ. Vaccination with DNA of the Mycobacterium tuberculosis 85B antigen protects mouse foot pad against infection with M. leprae. Int J Lepr Other Mycobact Dis 2001; 69:93-8; PMID:11757171.
80. Nomaguchi H, Mukai T, Takeshita F, Matsuoka M, Maeda Y, Aye TM, et al. Effect of hsp65 DNA vaccination carrying immunostimulatory DNA sequences (CpG motifs) against Mycobacterium leprae multiplication in mice. Int J Lepr Other Mycobact Dis 2002; 70:182-90; PMID:12483966.
81. Gelber RH, Mehra V, Bloom B, Murray LP, Siu P, Tsang M, et al. Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads. Infect Immun 1994; 62:4250-5; PMID:7927681.
82. Matsuoka M, Nomaguchi H, Yukitake H, Ohara N, Matsumoto S, Mise K, et al. Inhibition of multiplication of Mycobacterium leprae in mouse foot pads by immunization with ribosomal fraction and culture filtrate from Mycobacterium bovis BCG. Vaccine 1997; 15:1214-7; PMID:9286046; DOI:10.1016/S0264-410X(97) 00018-2.
83. Ohara N, Matsuoka M, Nomaguchi H, Naito M, Yamada T. Inhibition of multiplication of Mycobacterium leprae in mouse foot pads by recombinant Bacillus Catmette-Guerin (BCG). Vaccine 2000; 18:1294-7; PMID:10618524; DOI:10.1016/S0264-410X(99)00420-X.
84. Ohara N, Matsuoka M, Nomaguchi H, Naito M, Yamada T. Protective responses against experimental Mycobacterium leprae infection in mice induced by recombinant Bacillus Calmette-Guerin over-producing three putative protective antigen candidates. Vaccine 2001; 19:1906-10; PMID:11228360; DOI:10.1016/S0264-410X(00)00439-4.
85. Maeda Y, Mukai T, Spencer J, Makino M. Identification of an Immunomodulating Agent from Mycobacterium leprae. Infect Immun 2005; 73:2744-50; PMID:15845477; DOI:10.1128/IAI.73.5.2744-50.2005.
86. Makino M, Maeda Y, Ishii N. Immunostimulatory activity of major membrane protein-II from Mycobacterium leprae. Cell Immunol 2005; 233:53-60; PMID:15885677; DOI:10.1016/j.cell-imm.2005.04.001.
87. Makino M, Maeda Y, Inagaki K. Immunostimulatory activity of recombinant Mycobacterium bovis BCG that secretes major membrane protein II of Mycobacterium leprae. Infect Immun 2006; 74:6264-71; PMID:17057093; DOI:10.1128/IAI.00878-06.
88. Maeda Y, Tamura T, Matsuoka M, Makino M. Inhibition of the Multiplication of Mycobacterium leprae by Vaccination with a Recombinant BCG that Secretes Major Membrane Protein-II in Mice. Clin Vaccine Immunol 2009.
89. Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PE, Godfrey-Faussett P, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007; 25:14-8; PMID:16959383; DOI:10.1016/j.vaccine.2006.07.020.
90. Hesseling AC, Johnson LF, Jaspan H, Cotton MF, Whitelaw A, Schaaf HS, et al. Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants. Bull World Health Organ 2009; 87:505-11; PMID:19649364; DOI:10.2471/BLT.08.055657.
91. Nuttall JJ, Davies MA, Hussey GD, Eley BS. Bacillus Calmette-Guerin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. Int J Infect Dis 2008; 12:99-105; PMID:18799339; DOI:10.1016/j.ijid.2008.06.014.
92. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409:1007-11; PMID:11234002; DOI:10.1038/35059006.
93. Browne SG. Self-healing leprosy: report on 2,749 patients. Lepr Rev 1974; 45:104-11; PMID:4417433.
94. Ekambaram V, Sithambaram M. Self-healing in non-lepromatous leprosy in the area of the ELEP Leprosy Control Project Dharmapuri (Tamil Nadu). Lepr India 1977; 49:387-92; PMID:592741.
95. Duthie MS, Goto W, Ireton GC, Reece ST, Sampaio LH, Grassi AB, et al. Antigen-specific T-cell responses of leprosy patients. Clin Vaccine Immunol 2008; 15:1659-65; PMID:18784342; DOI:10.1128/CVI.00234-08.
96. Sampaio LH, Stefani MM, Oliveira RM, Sousa AL, Ireton GC, Reed SG, et al. Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis 2011; 11:26; PMID:21269435; DOI:10.1186/1471-2334-11-26.
97. Job CK, Sanchez RM, Hunt R, Truman RW, Hastings RC. Armadillos (Dasypus novemcinctus) as a model to test antileprosy vaccines; a preliminary report. Int J Lepr Other Mycobact Dis 1993; 61:394-7; PMID:8228437.
98. Scollard DM. Endothelial cells and the pathogenesis of lepromatous neuritis: insights from the armadillo model. Microbes Infect 2000; 2:1835-43; PMID:11165928; DOI:10.1016/S1286-4579(00)01335-6.
99. Scollard DM, Lathrop GW, Truman RW. Infection of distal peripheral nerves by M. leprae in infected armadillos; an experimental model of nerve involvement in leprosy. Int J Lepr Other Mycobact Dis 1996; 64:146-51; PMID:8690974.
100. Adams JE, Pena MT, Gillis TP, Williams DL, Adams LB, Truman RW. Expression of nine-banded armadillo (Dasypus novemcinctus) interleukin-2 in E. coli. Cytokine 2005; 32:219-25; PMID:16338142; DOI:10.1016/j.cyto.2005.09.011.
101. Peña MT, Adams JE, Adams LB, Gillis TP, Williams DL, Spencer JS, et al. Expression and characterization of recombinant interferon gamma (IFNgamma) from the nine-banded armadillo (Dasypus novemcinctus) and its effect on Mycobacterium leprae-infected macrophages. Cytokine 2008; 43:124-31; PMID:18558493; DOI:10.1016/j.cyto.2008.04.014.
102. Shepard CC. The experimental disease that follows the injection of human leprosy bacilli into foot-pads of mice. J Exp Med 1960; 112:445-54; PMID:19867175; DOI:10.1084/jem.112.3.445.
103. Truman RW, Andrews PK, Robbins NY, Adams LB, Krahenbuhl JL, Gillis TP. Enumeration of Mycobacterium leprae Using Real-Time PCR. PLoS Negl Trop Dis 2008; 2:328; PMID:18982056; DOI:10.1371/journal.pntd.0000328.
104. Duthie MS, Reece ST, Lahiri R, Goto W, Raman VS, Kaplan J, et al. Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear. Infect Immun 2007; 75:5290-7; PMID:17724073; DOI:10.1128/IAI.00564-07.
105. Raman VS, O'Donnell J, Bailor HR, Goto W, Lahiri R, Gillis TP, et al. Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection. Infect Immun 2009; 77:5623-30; PMID:19786561; DOI:10.1128/IAI.00508-09.
106. Moet FJ, Schuring RP, Pahan D, Oskam L, Richardus JH. The prevalence of previously undiagnosed leprosy in the general population of northwest bangladesh. PLoS Negl Trop Dis 2008; 2:198; PMID:18301731; DOI:10.1371/journal. pntd.0000198.
107. Schreuder PA, Liben DS, Wahjuni S, Van Den Broek J, De Soldenhoff R. A comparison of Rapid Village Survey and Leprosy Elimination Campaign, detection methods in two districts of East Java, Indonesia, 1997/1998 and 1999/2000. Lepr Rev 2002; 73:366-75; PMID:12549844.
108. Bakker MI, Hatta M, Kwenang A, Van Benthem BH, Van Beers SM, Klatser PR, et al. Prevention of leprosy using rifampicin as chemoprophylaxis. Am J Trop Med Hyg 2005; 72:443-8; PMID:15827283.
109. Nguyen LN, Cartel JL, Grosset JH. Chemoprophylaxis of leprosy in the Southern Marquesas with a single 25 mg/kg dose of rifampicin. Results after 10 years. Lepr Rev 2000; 71:33-5.
110. Diletto C, Blanc L, Levy L. Leprosy chemoprophylaxis in Micronesia. Lepr Rev 2000; 71:21-3.
111. Smith CM, Smith WC. Chemoprophylaxis is effective in the prevention of leprosy in endemic countries: a systematic review and meta-analysis. MILEP2 Study Group. Mucosal Immunology of Leprosy. J Infect 2000; 41:137-42; PMID:11023757; DOI:10.1053/jinf.2000.0698.
112. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev 2006; 19:338-81; PMID:16614253; DOI:10.1128/CMR.19.2.338-81.2006.
113. Wilkinson RJ, Lockwood DN. Antigenic trigger for type 1 reaction in leprosy. J Infect 2005; 50:242-3; PMID:15780420; DOI:10.1016/j.jinf.2004.02.012.
114. Zaheer SA, Mukherjee R, Ramkumar B, Misra RS, Sharma AK, Kar HK, et al. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J Infect Dis 1993; 167:401-10; PMID:8421173; DOI:10.1093/infdis/167.2.401.
115. Kaplan G, Britton WJ, Hancock GE, Theuvenet WJ, Smith KA, Job CK, et al. The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. J Exp Med 1991; 173:993-1006; PMID:2007862; DOI:10.1084/jem.173.4.993.
116. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175:1729-37; PMID:1588290; DOI:10.1084/jem.175.6.1729.
117. Girdhar BK, Girdhar A, Chakma JK. Advances in the treatment of reactions in leprosy. Indian J Lepr 2007; 79:121-34; PMID:18085170.
118. van Gompel A, van den Enden E, van den Ende J. Cyclosporin A is not very effective in erythema nodosum leprosum (ENL). Trop Geogr Med 1994; 46:331; PMID:7710538.
119. Uyemura K, Dixon JF, Wong L, Rea TH, Modlin RL. Effect of cyclosporine A in erythema nodosum leprosum. J Immunol 1986; 137:3620-3; PMID:2946765.
120. Talwar GP, Zaheer SA, Mukherjee R, Walia R, Misra RS, Sharma AK, et al. Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w in multibacillary leprosy patients. Vaccine 1990; 8:121-9; PMID:2336873; DOI:10.1016/0264-410X(90)90134-8.
121. Katoch K, Katoch VM, Natrajan M, Sreevatsa, Gupta UD, Sharma VD, et al. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy. Vaccine 2004; 22:3649-57; PMID:15315844; DOI:10.1016/j.vaccine.2004.03.037.
122. Narang T, Kaur I, Kumar B, Radotra BD, Dogra S. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy. Int J Lepr Other Mycobact Dis 2005; 73:105-14; PMID:16830653.
123. Stefani MM, Guerra JG, Sousa AL, Costa MB, Oliveira ML, Martelli CT, et al. Potential plasma markers of type 1 and type 2 leprosy reactions: a preliminary report. BMC Infect Dis 2009; 9:75; PMID:19473542; DOI:10.1186/1471-2334-9-75.
124. Scollard DM, Chaduvula MV, Martinez A, Fowlkes N, Nath I, Stryjewska BM, et al. Increased CXCL10 Levels and Gene Expression in Type 1 Leprosy Reactions. Clinical and vaccine immunology: CVI 2011.
125. Miller RA, Gorder D, Harnisch JP. Antibodies to phenolic glycolipid-I during long-term therapy: serial measurements in individual patients. Int J Lepr Other Mycobact Dis 1987; 55:633-6; PMID:3323367.
126. Chanteau S, Cartel JL, Celerier P, Plichart R, Desforges S, Roux J. PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy. Int J Lepr Other Mycobact Dis 1989; 57:735-43; PMID:2681456.
127. Meeker HC, Schuller-Levis G, Fusco F, Giardina-Becket MA, Sersen E, Levis WR. Sequential monitoring of leprosy patients with serum antibody levels to phenolic glycolipid-I, a synthetic analog of phenolic glycolipid-I and mycobacterial lipoarabinomannan. Int J Lepr Other Mycobact Dis 1990; 58:503-11; PMID:2205685.
128. Prakash K, Sehgal VN, Aggarwal R. Evaluation of phenolic glycolipid-I (PGL-I) antibody as a multidrug therapy (MDT) monitor. J Dermatol 1993; 20:16-20; PMID:8482747.
129. Rada E, Ulrich M, Aranzazu N, Rodriguez V, Centeno M, Gonzalez I, et al. A follow-up study of multibacillary Hansen's disease patients treated with multidrug therapy (MDT) or MDT + immunotherapy (IMT). Int J Lepr Other Mycobact Dis 1997; 65:320-7; PMID:9401484.
130. Cho SN, Cellona RV, Villahermosa LG, Fajardo TT Jr, Balagon MV, Abalos RM, et al. Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy. Clin Diagn Lab Immunol 2001; 8:138-42; PMID:11139208.
131. Roche PW, Britton WJ, Failbus SS, Neupane KD, Theuvenet WJ. Serological monitoring of the response to chemotherapy in leprosy patients. Int J Lepr Other Mycobact Dis 1993; 61:35-43; PMID:8326179.
132. Drowart A, Chanteau S, Huygen K, De Cock M, Cartel JL, De Bruyn J, et al. Effects of chemotherapy on antibody levels directed against PGL-I and 85A and 85B protein antigens in lepromatous patients. Int J Lepr Other Mycobact Dis 1993; 61:29-34; PMID:8326178.
133. Duthie MS, Goto W, Ireton GC, Reece ST, Cardoso LP, Martelli CM, et al. Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol 2007; 14:1400-8; PMID:17898185; DOI:10.1128/CVI.00299-07.
134. Nandan D, Venkatesan K, Katoch K, Dayal RS. Serum beta-glucuronidase levels in children with leprosy. Lepr Rev 2007; 78:243-7; PMID:18035775.
135. Perrin FM, Lipman MC, McHugh TD, Gillespie SH. Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect Dis 2007; 7:481-90; PMID:17524807; DOI:10.1016/S1473-3099(07)70112-3.
136. Kaufmann SH, Parida SK. Tuberculosis in Africa: learning from pathogenesis for biomarker identification. Cell Host Microbe 2008; 4:219-28; PMID:18779048; DOI:10.1016/j.chom.2008.08.002.
137. Walzl G, Ronacher K, Djoba Siawaya JF, Dockrell HM. Biomarkers for TB treatment response: challenges and future strategies. J Infect 2008; 57:103-9; PMID:18649943; DOI:10.1016/j.jinf.2008.06.007.
138. Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, et al. Biomarkers for tuberculosis disease activity, cure and relapse. Lancet Infect Dis 2009; 9:162-72; PMID:19246020; DOI:10.1016/S1473-3099(09)70042-8.
139. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, Peri G, et al. IFNgamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005; 7:1-8; PMID:15716076; DOI:10.1016/j.micinf. 2004.09.004.
140. Azzurri A, Kanaujia GV, Sow OY, Bah B, Diallo A, Del Prete G, et al. Serological markers of pulmonary tuberculosis and of response to anti-tuberculosis treatment in a patient population in Guinea. Int J Immunopathol Pharmacol 2006; 19:199-208; PMID:16569358.
141. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004; 38:754-6; PMID:14986262; DOI:10.1086/381754.
142. Higuchi K, Harada N, Mori T. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology 2008; 13:468-72; PMID:18399875; DOI:10.1111/j.1440-843.2008.01244.x.
143. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006; 174:831-9; PMID:16799072; DOI:10.1164/rccm.200511-1783OC.
144. Veenstra H, Crous I, Brahmbhatt S, Lukey P, Beyers N, van Helden PD, et al. Changes in the kinetics of intracellular IFNgamma production in TB patients during treatment. Clin Immunol 2007; 124:336-44; PMID:17616440; DOI:10.1016/j.clim.2007.05.014.